Prognostic Relevance of Transforming Genes

Schlegel, Uwe; Neumann, Jürgen; Kindermann, D; Wolf, H.; Baumann, Axel; Förster, Frank; Fimmers, R.

doi:10.1007/978-3-642-85039-4_6

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference might explain an age-related variation in gliomagenesis. At the protein level, overexpression can range from 6% to 89% of reported cases of glioma, due to unknown mechanisms (24, 27, 28, 33, 37-60, 130, 132, 135-137). The EGFRvIII mutation was found in 8%-14% of anaplastic astrocytomas and 0% of oligoastrocytomas (34, 98).…”

Section: Egfr In Other Gliomasmentioning

confidence: 99%

See 1 more Smart Citation

EGFR as a clinical marker in glioblastomas and other gliomas

2017

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a member of the tyrosine kinase superfamily receptor. Gliomas are tumors originating from glial cells, which show a range of aggressiveness depending on grade and stage. Many EGFR gene alterations have been identified in gliomas, especially glioblastomas, including amplifications, deletions and single nucleotide polymorphisms (SNPs). Glioblastomas are discussed as a separate entity due to their high correlation with EGFR mutants and the reported association of the latter with survival and response to treatment in this glioma subgroup. This review is a comprehensive report of EGFR gene alterations and their relations with several clinical factors in glioblastomas and other gliomas. It covers all EGFR gene alterations including point mutations, SNPs, methylations, copy number variations and amplifications, assessed with regard to different clinical variables, including response to therapy and survival. This review also discusses the current prognostic status of EGFR in glioblastomas and other gliomas, and highlights gaps in previous studies. This serves as an update for the medical community about the role of EGFR gene alterations in gliomas and specifically glioblastomas, as a means for targeted treatment and prognosis.

show abstract

Section: Egfr In Other Gliomasmentioning

confidence: 99%

“…EGFR overexpression was seen in 6%-28%, 27%-70% and 22%-89% of grade II, III and IV astrocytomas, respectively (24, 27, 28, 33, 37-60). Overexpression was associated with tumor grade and with PFS and OS (24, 33, 38-40, 42, 44, 49-51, 53, 56, 57).…”

Section: Egfr In Other Gliomasmentioning

confidence: 99%

EGFR as a clinical marker in glioblastomas and other gliomas

2017

View full text Add to dashboard Cite

show abstract

Prognostic Significance of EGFR Gene Amplification and Overexpression in Diffuse Astrocytomas—A Literature Study

Hagen¹,

Torp²

2012

OJPathology

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) has been shown to play an important role in the malignant progression of diffuse astrocytomas. Numerous studies have investigated the clinical significance of overexpression and amplification of the EGFR gene in these tumours with ambiguous results. The aim of this study was therefore to review the literature to get the current prognostic and diagnostic status. The PubMed database was used to search for papers in English in the time period 1987-2010 using the following keywords: astrocytoma, glioma, c-erbB1, EGFR, glioblastoma, HER1 and prognosis. Other inclusion criteria were: 1) studies with more than 50 patients; 2) patient age over 18 years; 3) tumour grading according to the latest World Health Organization (WHO) classification (2007) and 4) EGFR overexpression assessed by immunohistochemistry. A total of 47 publications were included and several reported positive correlations between both EGFR gene amplification and overexpression with histological malignancy grade and survival. The results are, however, encumbered with elements of uncertainty involving for instance methodological diversities and small number of patients. Larger studies with standardized procedures are necessary to fully clarify the clinical role of EGFR in human astrocytomas.

show abstract

Prognostic Relevance of Transforming Genes

Cited by 2 publications

References 23 publications

EGFR as a clinical marker in glioblastomas and other gliomas

EGFR as a clinical marker in glioblastomas and other gliomas

Prognostic Significance of EGFR Gene Amplification and Overexpression in Diffuse Astrocytomas—A Literature Study

Contact Info

Product

Resources

About